[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341680-105":59,"doc-detail-341680-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","application-of-comprehensive-molecular-genetic-profiling-in-precision-cancer-medicine-hungarian-experiences","Application of comprehensive molecular genetic profiling in precision cancer medicine - Hungarian experiences","","Recent advances in molecular genetic testing methods, including next-generation sequencing (NGS) panels, have accelerated the identification of actionable genetic alterations for targeted cancer therapy. Hungary implemented a centralized approval process coordinated through the National Molecular Tumor Board to manage comprehensive genetic profiling (CGP), covering patient selection and therapy reimbursement. CGP entered routine care in 2021 using large NGS gene panels (>500 genes). From 2021 to Aug 2023, 163 cases were tested, 45% showed clinically relevant alterations, 14.7% received targeted therapy, and a positive clinical response occurred in 8.5% of cases.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/application-of-comprehensive-molecular-genetic-profiling-in-precision-cancer-medicine-hungarian-experiences/341680/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/application-of-comprehensive-molecular-genetic-profiling-in-precision-cancer-medicine-hungarian-experiences/341680.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of comprehensive genetic profiling (CGP) in precision cancer medicine?","Question",{"text":113,"@type":114},"CGP aims to identify molecularly targetable genetic alterations so patients can receive the most appropriate targeted therapeutic interventions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was CGP implemented and approved in Hungary?",{"text":118,"@type":114},"Hungary launched a centralized approval system based on recommendations from the National Molecular Tumor Board, coordinating patient selection and therapy reimbursement for CGP.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main results from 163 tested cases in the study?",{"text":122,"@type":114},"Clinically relevant genetic alterations were found in 74 cases (45%). In 24 patients (14.7%), targeted therapy was administered based on CGP results, with positive clinical response in 8.5% of tested cases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341680,1790383764,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","SHORT REPORT  \nApplication of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences  \nErika Tótha,b , Zsófia Küronyaa,c , Edina Soósa,c, Tamás Pintéra,c , Henriett Butza,d,e,f , Zsolt Horvátha,c , Erzsébet Csernáka,b, Vince Kornél, Grolmusza,d,e , Judit Székelya,g, Tamás Strausza,b, József Löveya,h , Levente Jánvária,h, László Báthory-Fülöpa,b, Péter Nagya,i , Csaba Polgára,j  and Attila Patócsa,d,e   \na National Institute of Oncology, National Tumor Biology Laboratory, Budapest, Hungary; bDepartment of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary; c Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary; dDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary; e HUNREN Hereditary Cancer Research Group, Budapest, Hungary; fCentral Biobank, National Institute of Oncology, Budapest, Hungary; gCenter of Radiotherapy, National Institute of Oncology, Budapest, Hungary; hCenter of Radiotherapy, National Institute of Oncology, Budapest, Hungary; iDepartment of Molecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary; jCenter of Radiotherapy, National Institute of Oncology, Budapest, Hungary  \nABSTRACT  \nRecent developments in molecular genetic testing methods ([e.g. next-generation](e.g. next-generation) sequencing [NGS]-panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement.  \nAim: The study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An NGS-based large (> 500 genes) gene panel was used for cases where molecular genetic testing was approved by the National Molecular Tumor Board. From 2021 until August 2023 163 cases were tested. The majority of them were ECOG 0–1 patients with advanced-stage diseases, histologically rare cancer, or cancers with unknown primary tumours.  \nResults: Seventy-four cases (74 of 163, 45%) had clinically relevant genetic alterations. In 34 patients, the identified variants represented an indication for an approved therapy (approved by the Hungarian authorities, on-label indication), while in 40 cases the recommended therapy did not have an approved indication in Hungary for certain tumour types, but off-label indication could be recommended. Based on our CGP results, 24 patients (24/163; 14.7%) received targeted therapy. Treatment duration was between 1 and 60 months. In total 14 (14/163; 8.5% of the tested cases) patients had a positive clinical response (objective response or stable disease) and were treated for more than 16 weeks.  \nInterpretation: NGS-based CGP was successfully introduced in our institution and a significant number of patients benefited from comprehensive genetic tests. Our preliminary results can serve as the starting point of Drug Rediscovery Protocol (DRUP) studies.  \nARTICLE HISTORY  \nReceived 19 January 2024 Accepted 28 May 2024 Published 16 June 2024  \nKEYWORDS  \nTumour mutation profile; molecular tumour board; targeted therapy  \nBackground  \nIn routine clinical practice various molecular genetic tests are used for the identification of therapeutically actionable genetic variants. Single gene tests, various-sized gene panels, or largescale genetic analyses evaluating > 500 genes, whole exome, and whole genome sequencing are available. In our routine clinical practice, the next-generation sequencing (NGS) approach that uses a single assay to assess approximately 500 genes and genetic variants","cbCaiafbQpUKXhQ0","https://ap.wps.com/l/cbCaiafbQpUKXhQ0","pdf",908579,"English","# Abstract\n# Keywords\n# Background","[{\"question\":\"What is the purpose of comprehensive genetic profiling (CGP) in precision cancer medicine?\",\"answer\":\"CGP aims to identify molecularly targetable genetic alterations so patients can receive the most appropriate targeted therapeutic interventions.\"},{\"question\":\"How was CGP implemented and approved in Hungary?\",\"answer\":\"Hungary launched a centralized approval system based on recommendations from the National Molecular Tumor Board, coordinating patient selection and therapy reimbursement for CGP.\"},{\"question\":\"What were the main results from 163 tested cases in the study?\",\"answer\":\"Clinically relevant genetic alterations were found in 74 cases (45%). In 24 patients (14.7%), targeted therapy was administered based on CGP results, with positive clinical response in 8.5% of tested cases.\"}]","Application of comprehensive molecular genetic profiling in precision cancer medicine - Hungarian experiences | PDF",1790043163,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad3ac29b24ad043e93d9a83e72fdfff2.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/055f67861ba6cf543ed671cfcc165c62.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdf416fba006ad8f78fc1b847fd6a488.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f89935db666a2214fc4272c1f62e65ea.webp",980,1276]